D-Leucine amide-CDDO-Me-HMP

Overview

D-Leucine amide-CDDO-Me-HMP is a prodrug composed of CDDO-Me ( HY-13324 ) and ligustrazine ( HY-N0264 ). D-Leucine amide-CDDO-Me-HMP can protect against CCl 4 -induced liver injury. D-Leucine amide-CDDO-Me-HMP can inhibit ROS production, alleviates mitochondrial damage and inhibits cell apoptosis . D-Leucine amide-CDDO-Me-HMP can be used for the research of liver injury.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Disease | Products > Disease Areas > Liver Injury | Products > Signaling Pathways > Others | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Keap1-Nrf2 | Products > Signaling Pathways > Heme Oxygenase (HO) | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Drug Intermediate | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-179613
• CAS No.: 2749600-16-4
• Molecular Formula: C53H73N5O6
• Molecular Weight: 876.18
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source